Could antidepressant results be amongst the unanticipated advantages of glucagon-like peptide (GLP-1) therapies?
In a latest examine, researchers at Southeast University and Huazhong University of Science and Technology discovered that GLP-1 therapy alleviates depression-like behaviors by altering the intestine microbiome. The findings have been lately printed in Cell Host & Microbe.
The unclear relationship between GLP-1s and temper
Following a meal, intestine cells naturally produce GLP-1. The hormone mediates satiety by slowing gastric emptying and signaling to the mind, and it additionally performs a task in blood glucose management.
GLP-1 receptor agonists have been developed based mostly on this data, aiming to imitate the hormone’s pure operate to deal with circumstances resembling diabetes and power weight problems.
Since the approval of semaglutide for weight reduction in 2021, widespread use of GLP-1 receptor agonists has skyrocketed.
This has revealed each hidden risks and rewards.
As properly as turning down the dial on “food noise”, some customers have reported optimistic results on temper, whereas others really feel emotionally flat.
Studies have offered conflicting proof on the neuropsychiatric results of GLP-1s, reflecting broader uncertainty about the class and its long-term results.
“Some studies reported antidepressant effects of GLP-1 agonists, while others suggested increased risk of depression or anxiety,” commented Dr. Yong Gui Yuan, head of psychosomatics and psychiatry at Southeast University.
Given that overweight people face a bidirectional relationship with psychological well being circumstances, in addition to potential for GLP-1 misuse amongst people with eating disorders, it is very important characterize their affect on psychological well being to each maximize profit and mitigate hurt.
Uncovering a GLP-1 receptor-independent pathway
The researchers got down to perceive the relationship between GLP-1 therapies and despair, particularly whether or not they have an effect on the intestine microbiome to modulate temper.
Changes in gut microbiota composition have been noticed throughout a number of psychological well being circumstances, and several other research have demonstrated its significance in depression.
The staff started by analyzing blood samples from 70 contributors, obtained underneath fasting circumstances. They discovered that people with main depressive problems (MDD) had decrease ranges of GLP-1 hormone of their blood in comparison with wholesome controls, and that more and more decrease GLP-1 ranges have been related to worsening despair and nervousness scores.
In mouse fashions of power unpredictable stress (CUS) the identical correlation was noticed.
This prompted the staff to research whether or not GLP-1 exercise “supplementation” with liraglutide could possibly be used to deal with despair.
Interestingly, handled CUS mice didn’t profit from lowered urge for food or weight reduction, the hallmarks of GLP-1 use, however did exhibit enhancements in traits of despair. These findings prompt that any antidepressant-like results are impartial of the medication’ metabolic actions.
Researchers then pharmacologically blocked GLP-1 receptor signaling to residence in on the potential mechanism. Liraglutide continued to alleviate depression-like behaviors, pointing to a GLP-1 receptor-independent pathway. When antidepressant results persevered after administering the remedy to world GLP-1 receptor knockout mice, their suspicions have been confirmed.
GLP-1s, the intestine microbiome, and temper
Seeking to find out precisely how the drug induced these results, the researchers used fluorescently tagged liraglutide to trace its distribution.
“We observed that when we systemically administered liraglutide to the mice, it accumulated predominantly in the intestine rather than the brain,” famous Dr. Bing Han, senior analysis fellow.
This led the staff to hypothesize that the antidepressant results of liraglutide could possibly be microbiome-mediated. This principle was supported when the liraglutide’s suspected profit disappeared in each intestine microbiome-depleted and germ-free mice.
The researchers then delved deeper, utilizing fecal pattern evaluation, to research particular microbiome modifications. Liraglutide was discovered to revive ranges of Lactobacillus delbrueckii, a intestine microbe lowered in CUS fashions. Increasing Lactobacillus ranges has beforehand been proven to improve MDD symptoms in sufferers.
Microbiome-depleted CUS mice have been then given fecal microbiota transplants from untreated and liraglutide-treated CUS donors. In handled donors, L. delbrueckii ranges elevated, and depression-like behaviors improved.
Fecal and plasma metabolomics have been later used to map the underlying sequence of occasions. The evaluation prompt that liraglutide alters the metabolic exercise of L. delbrueckii, not directly selling the manufacturing of 2-arachidonoylglycerol (2-AG), a chemical messenger concerned in temper and emotional regulation.
Finally, that they had linked the dots between liraglutide, the microbiome, and temper.
GLP-1s present promise for metabolic and psychological well being
In questioning how GLP-1 therapies might alter temper, this examine not solely offered preclinical causal proof but in addition a possible therapeutic goal.
The pathways described might additionally function the foundations for microbiome-mediated antidepressant therapies.
Having been carried out in male mice, the outcomes would have to be replicated by means of human gut microbiota research, given each species and intercourse variations in gastrointestinal anatomy and physiology, microbiome range, and neurobiology.
Although semaglutide administration demonstrated a sample much like liraglutide on this examine, future analysis would profit from investigating different GLP-1s to substantiate any class-wide mechanisms.
The examine gives early proof behind the psychological well being advantages, not simply metabolic advantages, that GLP-1 therapies might present.
Reference: Bian L, Cai Y, Zhang Y, et al. Microbiota-driven gut-brain signaling underlies antidepressant results of a GLP-1 analog. Cell Host Microbe. 2026;34(6):1000-1017.e5. doi: 10.1016/j.chom.2026.05.003
This article is a rework of a press launch issued by Cell Press. Material has been edited for size and content material.